Table 4.
Median Measles PRNa Titers Pre- and Postimmunization With 1 or 2 Doses of Measles-Containing Vaccine in HIV-Infected and Uninfected Children Born to HIV-Infected Mothers
| Treatment group |
||||||||
|
2DNEG |
2DPOS |
1DNEG |
1DPOS |
|||||
| Study week | Number | Median PRN titer mIU/mL (Q1, Q3) | Number | Median PRN titer mIU/mL (Q1, Q3) | Number | Median PRN titer mIU/mL (Q1, Q3) | Number | Median PRN titer mIU/mL (Q1, Q3) |
| Week 0b | 63 | 8 (8, 39) | 7 | 8 (8, 43) | 26 | 8 (8, 32) | 8 | 8(8,12) |
| Week 6 | 61 | 628 (192, 1448) | 7 | 2115 (695, 2722) | NA | NA | NA | NA |
| Week 16 | 61 | 910 (311, 1907) | 6 | 966 (282, 2435) | NA | NA | NA | NA |
| Week 26c | 62 | 1090 (472, 2212) | 5 | 1569 (306, 2490) | 22 | 2 (2, 2) | 7 | 2 (2,2) |
| Week 32 | 56 | 3445 (1972, 5027) | 6 | 2830 (529, 4956) | 22 | 3240 (1525, 4371) | 7 | 2702 (1351, 5839) |
| Week 42 | 49 | 2353 (1297, 3566) | 5 | 321 (301, 3369) | 21 | 3273 (1360, 4467) | 7 | 2149 (969, 4562) |
| Week 52 | 54 | 1468 (779, 2947) | 5 | 353 (229, 2478) | 23 | 3125 (1693, 4565) | 6 | 2428 (237, 4290) |
| Week 104 | 42 | 1049 (715, 2353) | 6 | 1612 (293, 2628) | 16 | 5602 (1806, 8200) | 6 | 696 (171, 1687) |
| Week 130 | 41 | 9671 (628, 2364) | 5 | 867 (358, 1893) | 17 | 3465d (2395, 8200) | 6 | 573 (111, 2048) |
NOTE. aPRN indicates plaque reduction neutralization.
b
Time point at which 2DNEG and 2DPOS children were immunized with measles vaccine at 6 months of age (study week 0).
c
Time point at which all children (2DPOS, 2DNEG, 1DPOS and 1DNEG) were given MMRII at 12 months of age.
d
Median measles PRN titer in the 1DNEG group was significantly higher than the median PRN titer in the 2DNEG group with Monte Carlo–estimated P value <.001 calculated using the Wilcoxon signed rank test.